UNITED LAB (03933): Cefoperazone Sodium and Sulbactam Sodium for Injection Passes Consistency Evaluation

Stock News11-26

UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration for the consistency evaluation of its Cefoperazone Sodium and Sulbactam Sodium for Injection (specification: 2.0g).

Cefoperazone Sodium and Sulbactam Sodium for Injection is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity, suitable for monotherapy or combination therapy. As a standalone treatment, it is indicated for respiratory tract infections, urinary tract infections, intra-abdominal infections, septicemia, meningitis, skin and soft tissue infections, bone and joint infections, and reproductive tract infections caused by susceptible bacteria. It demonstrates significant therapeutic effects against inflammation and infections caused by sensitive bacteria, effectively controlling inflammatory responses.

Currently, the drug is listed as a Class B medication in China's National Reimbursement Drug List (2024 Edition). This approval is expected to further strengthen the company's leading position in the anti-infective sector. UNITED LAB remains committed to new product development and advancing consistency evaluations, which is anticipated to generate greater returns for the company and its shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196299660?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 17:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196299660","market":"nz","top_or_hot":-1,"title":"UNITED LAB (03933): Cefoperazone Sodium and Sulbactam Sodium for Injection Passes Consistency Evaluation","media":"Stock News","content":"<p>UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration for the consistency evaluation of its Cefoperazone Sodium and Sulbactam Sodium for Injection (specification: 2.0g).</p>\n<p>Cefoperazone Sodium and Sulbactam Sodium for Injection is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity, suitable for monotherapy or combination therapy. As a standalone treatment, it is indicated for respiratory tract infections, urinary tract infections, intra-abdominal infections, septicemia, meningitis, skin and soft tissue infections, bone and joint infections, and reproductive tract infections caused by susceptible bacteria. It demonstrates significant therapeutic effects against inflammation and infections caused by sensitive bacteria, effectively controlling inflammatory responses.</p>\n<p>Currently, the drug is listed as a Class B medication in China's National Reimbursement Drug List (2024 Edition). This approval is expected to further strengthen the company's leading position in the anti-infective sector. UNITED LAB remains committed to new product development and advancing consistency evaluations, which is anticipated to generate greater returns for the company and its shareholders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UNITED LAB (03933): Cefoperazone Sodium and Sulbactam Sodium for Injection Passes Consistency Evaluation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUNITED LAB (03933): Cefoperazone Sodium and Sulbactam Sodium for Injection Passes Consistency Evaluation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-26 17:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration for the consistency evaluation of its Cefoperazone Sodium and Sulbactam Sodium for Injection (specification: 2.0g).</p>\n<p>Cefoperazone Sodium and Sulbactam Sodium for Injection is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity, suitable for monotherapy or combination therapy. As a standalone treatment, it is indicated for respiratory tract infections, urinary tract infections, intra-abdominal infections, septicemia, meningitis, skin and soft tissue infections, bone and joint infections, and reproductive tract infections caused by susceptible bacteria. It demonstrates significant therapeutic effects against inflammation and infections caused by sensitive bacteria, effectively controlling inflammatory responses.</p>\n<p>Currently, the drug is listed as a Class B medication in China's National Reimbursement Drug List (2024 Edition). This approval is expected to further strengthen the company's leading position in the anti-infective sector. UNITED LAB remains committed to new product development and advancing consistency evaluations, which is anticipated to generate greater returns for the company and its shareholders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1196299660","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196299660","pubTimestamp":1764148349,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药","BK1191":"制药"},"translate_title":"联邦制药(03933)：注射用头孢哌酮钠舒巴坦钠通过一致性评价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration for the consistency evaluation of its Cefoperazone Sodium and Sulbactam Sodium for Injection (specification: 2.0g).\nCefoperazone Sodium and Sulbactam Sodium for Injection is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity, suitable for monotherapy or combination therapy. As a standalone treatment, it is indicated for respiratory tract infections, urinary tract infections, intra-abdominal infections, septicemia, meningitis, skin and soft tissue infections, bone and joint infections, and reproductive tract infections caused by susceptible bacteria. It demonstrates significant therapeutic effects against inflammation and infections caused by sensitive bacteria, effectively controlling inflammatory responses.\nCurrently, the drug is listed as a Class B medication in China's National Reimbursement Drug List (2024 Edition). This approval is expected to further strengthen the company's leading position in the anti-infective sector. UNITED LAB remains committed to new product development and advancing consistency evaluations, which is anticipated to generate greater returns for the company and its shareholders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196299660","isCrawlerRequest":true}